Alternative splicing as a biomarker and potential target for drug discovery

Acta Pharmacol Sin. 2015 Oct;36(10):1212-8. doi: 10.1038/aps.2015.43. Epub 2015 Jun 15.

Abstract

Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alternative Splicing* / drug effects
  • Animals
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / genetics*
  • Drug Discovery* / methods
  • Genetic Markers / genetics
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / genetics*
  • RNA, Messenger / genetics*

Substances

  • Genetic Markers
  • RNA, Messenger